SCHEMBL6995647

SCHEMBL6995647

CCOC(=O)c1c(Nc2cc(F)ccc2N)sc2cc(Br)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.40
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
SMN1; SMN2 Q16637 5/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
KDM4E B2RXH2 2/20 0.40
GRM6 O15303 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
RECQL P46063 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALOX15 P16050 2/20 0.39
GAA P10253 2/20 0.39
TSHR P16473 1/20 0.39
RPS6KB1 P23443 1/20 0.39
CDK2 P24941 1/20 0.39
MAPKAPK2 P49137 1/20 0.39
GSK3B P49841 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6995665 0.90 MAPT (0.41) MAPTMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL7000919 0.87 PRKCZ (0.44) MAPTMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL6993864 0.87 SMN1; SMN2 (0.43) MAPTSMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL6990165 0.85 MAPT (0.38) MAPTMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL6991553 0.85 SMN1; SMN2 (0.43) MAPTMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL6997282 0.79 SMN1; SMN2 (0.51) MAPTMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL7000437 0.79 SMN1; SMN2 (0.43) MAPTKMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL6999000 0.79 IDO1 (0.44) MAPTMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL6992504 0.76 SMN1; SMN2 (0.55) MAPTMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL6996750 0.76 SMN1; SMN2 (0.45) MAPTMEN1KMT2ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT MAPT 15/4885MEN1 1756/4885KMT2A 2923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.